Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression

Prostate

Volumn 73, Issue 11, 2013, Pages 1191-1201

  Mavridis, Konstantinos ^a   Stravodimos, Konstantinos ^a   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

biochemical relapse; biological tumor markers; kallikrein related peptidases; kallikreins; KLKs; prostate cancer biomarker

Indexed keywords

COMPLEMENTARY DNA; KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 15; MESSENGER RNA; PEPTIDASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DNA SYNTHESIS; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE TUMOR; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84879359041     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22667     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90.
2. Ulmert D, O'Brien MF, Bjartell AS, Lilja H,. Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol 2009; 6 (7): 384-391.
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360 (13): 1320-1328.
4. Stephan C, Jung K, Lein M, Diamandis EP,. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 2007; 43 (13): 1918-1926.
5. Diamandis EP,. Prostate cancer screening with prostate-specific antigen testing: More answers or more confusion ? Clin Chem 2010; 56 (3): 345-351.
6. Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ,. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer 2009; 101 (11): 1833-1838.
7. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM,. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level. Cancer 2006; 106 (7): 1507-1513.
8. Sardana G, Dowell B, Diamandis EP,. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 2008; 54 (12): 1951-1960.
9. Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, Scardino PT, Schroder F, Lilja H,. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: An independent replication. J Clin Oncol 2010; 28 (15): 2493-2498.
10. Overdevest JB, Theodorescu D, Lee JK,. Utilizing the molecular gateway: The path to personalized cancer management. Clin Chem 2009; 55 (4): 684-697.
11. Avgeris M, Mavridis K, Scorilas A,. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: From pathobiology to clinical relevance. Biol Chem 2012; 393 (5): 301-317.
12. Mavridis K, Scorilas A,. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol 2010; 6 (2): 269-285.
13. Avgeris M, Mavridis K, Scorilas A,. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol Chem 2010; 391 (5): 505-511.
14. Borgono CA, Diamandis EP,. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4 (11): 876-890.
15. Kontos CK, Scorilas A,. Kallikrein-related peptidases (KLKs): A gene family of novel cancer biomarkers. Clin Chem Lab Med CCLM/FESCC 2012; 50 (11): 1877-1891.
16. Scorilas A, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros N, Pagano F, Diamandis EP,. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Prostate 2003; 54 (3): 220-229.
17. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaipillai AR, Diamandis EP,. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res 2003; 63 (19): 6543-6546.
18. Avgeris M, Stravodimos K, Scorilas A,. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance. Prostate 2011; 71 (16): 1780-1789.
19. Rabien A, Fritzsche F, Jung M, Diamandis EP, Loening SA, Dietel M, Jung K, Stephan C, Kristiansen G,. High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse. Tumour Biol 2008; 29 (1): 1-8.
20. Yousef GM, Stephan C, Scorilas A, Ellatif MA, Jung K, Kristiansen G, Jung M, Polymeris ME, Diamandis EP,. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 2003; 56 (4): 287-292.
21. Rabien A, Fritzsche FR, Jung M, Tolle A, Diamandis EP, Miller K, Jung K, Kristiansen G, Stephan C,. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. Int J Cancer 2010; 127 (10): 2386-2394.
22. Mavridis K, Avgeris M, Koutalellis G, Stravodimos K, Scorilas A,. Expression analysis and study of the KLK15 mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Cancer Sci 2010; 101 (3): 693-699.
23. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Bharaj BS, Nakamura T, Loening SA, Diamandis EP,. Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J Urol 2003; 169 (1): 361-364.
24. Sterbis JR, Gao C, Furusato B, Chen Y, Shaheduzzaman S, Ravindranath L, Osborn DJ, Rosner IL, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S, Cullen J, Petrovics G,. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clin Cancer Res 2008; 14 (3): 758-763.
25. Korbakis D, Gregorakis AK, Scorilas A,. Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: An independent cancer biomarker. Clin Chem 2009; 55 (5): 904-913.
26. Yousef GM, Scorilas A, Chang A, Rendl L, Diamandis M, Jung K, Diamandis EP,. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate 2002; 51 (2): 126-132.
27. Stavropoulou P, Gregorakis AK, Plebani M, Scorilas A,. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin Chim Acta 2005; 357 (2): 190-195.
28. Yousef GM, Scorilas A, Jung K, Ashworth LK, Diamandis EP,. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem 2001; 276 (1): 53-61.
29. Batra J, Nagle CM, O'Mara T, Higgins M, Dong Y, Tan OL, Lose F, Skeie LM, Srinivasan S, Bolton KL, Song H, Ramus SJ, Gayther SA, Pharoah PD, Kedda MA, Spurdle AB, Clements JA,. A kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival. BMC Cancer 2011; 11: 119.
30. Takayama TK, Carter CA, Deng T,. Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 2001; 40 (6): 1679-1687.
31. Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgono C, de la Longrais IAR, Puopolo M, Massobrio M, Diamandis EP,. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol 2003; 21 (16): 3119-3126.
32. Yousef GM, Scorilas A, Magklara A, Memari N, Ponzone R, Sismondi P, Biglia N, Abd Ellatif M, Diamandis EP,. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br J Cancer 2002; 87 (11): 1294-1300.
33. Batra J, Lose F, O'Mara T, Marquart L, Stephens C, Alexander K, Srinivasan S, Eeles RA, Easton DF, Al Olama AA, Kote-Jarai Z, Guy M, Muir K, Lophatananon A, Rahman AA, Neal DE, Hamdy FC, Donovan JL, Chambers S, Gardiner RA, Aitken J, Yaxley J, Kedda MA, Clements JA, Spurdle AB,. Association between prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. PLoS ONE 2011; 6 (11): e26527.
34. Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, Teillac P, Tunn UW,. Management of prostate-specific antigen relapse in prostate cancer: A European consensus. Int J Clin Pract 2004; 58 (4): 382-390.
35. Koistinen H, Paju A, Koistinen R, Finne P, Lovgren J, Wu P, Seppala M, Stenman UH,. Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate 2002; 50 (2): 112-118.
36. Rehault S, Monget P, Mazerbourg S, Tremblay R, Gutman N, Gauthier F, Moreau T,. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 2001; 268 (10): 2960-2968.
37. Hekim C, Riipi T, Weisell J, Narvanen A, Koistinen R, Stenman UH, Koistinen H,. Identification of IGFBP-3 fragments generated by KLK2 and prevention of fragmentation by KLK2-inhibiting peptides. Biol Chem 2010; 391 (4): 475-479.
38. Gao L, Smith RS, Chen LM, Chai KX, Chao L, Chao J,. Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. Biol Chem 2010; 391 (7): 803-812.
39. Mize GJ, Wang W, Takayama TK,. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2. Mol Cancer Res 2008; 6 (6): 1043-1051.
40. Ramsay AJ, Dong Y, Hunt ML, Linn M, Samaratunga H, Clements JA, Hooper JD,. Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. J Biol Chem 2008; 283 (18): 12293-12304.
41. Wang W, Mize GJ, Zhang X, Takayama TK,. Kallikrein-related peptidase-4 initiates tumor-stroma interactions in prostate cancer through protease-activated receptor-1. Int J Cancer 2010; 126 (3): 599-610.
42. Pampalakis G, Sotiropoulou G,. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta 2007; 1776 (1): 22-31.
43. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol DL, Clements JA,. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 2005; 12 (3): 631-643.
44. Gao J, Collard RL, Bui L, Herington AC, Nicol DL, Clements JA,. Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate 2007; 67 (4): 348-360.
45. Goya M, Ishii G, Miyamoto S, Hasebe T, Nagai K, Yonou H, Hatano T, Ogawa Y, Ochiai A,. Prostate-specific antigen induces apoptosis of osteoclast precursors: Potential role in osteoblastic bone metastases of prostate cancer. Prostate 2006; 66 (15): 1573-1584.
46. Mavridis K, Talieri M, Scorilas A,. KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. Biol Chem 2010; 391 (4): 467-474.
47. Thomadaki H, Mavridis K, Talieri M, Scorilas A,. Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. Thromb Haemost 2009; 101 (2): 373-380.
48. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169 (2): 517-523.
49. Shariat SF, Karakiewicz PI, Suardi N, Kattan MW,. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: A critical analysis of the literature. Clin Cancer Res 2008; 14 (14): 4400-4407.